Daily Sepsis Research Analysis
Three studies reshape sepsis management across treatment timing, risk stratification, and resuscitation strategy. A large Japanese database analysis supports using JAAM-2-DIC to guide when to start anticoagulation, a multicenter cohort shows FI-lab plus lymphocyte patterns predict 28-day mortality in older adults, and a meta-analysis of RCTs finds restrictive fluids are safe but not superior in septic shock.
Summary
Three studies reshape sepsis management across treatment timing, risk stratification, and resuscitation strategy. A large Japanese database analysis supports using JAAM-2-DIC to guide when to start anticoagulation, a multicenter cohort shows FI-lab plus lymphocyte patterns predict 28-day mortality in older adults, and a meta-analysis of RCTs finds restrictive fluids are safe but not superior in septic shock.
Research Themes
- Coagulation-targeted therapy timing in sepsis (DIC initiation criteria)
- Geriatric sepsis risk stratification and immunophenotyping
- Fluid resuscitation strategies in septic shock
Selected Articles
1. The modified Japanese Association for Acute Medicine disseminated intravascular coagulation diagnostic criteria in sepsis is useful for an indicator of initiating treatment for disseminated intravascular coagulation.
Using a nationwide Japanese claims database (n=1,903 sepsis patients), DIC anticoagulation (recombinant thrombomodulin, antithrombin) improved survival only in patients meeting DIC criteria, while increasing transfusion-requiring bleeding in those without DIC. JAAM-2-DIC uniquely identified patients with benefit and acceptable safety, outperforming ISTH overt DIC and SIC for treatment decision-making.
Impact: Provides practice-informing evidence that anticoagulation for sepsis-associated DIC should be triggered by JAAM-2-DIC, balancing efficacy and bleeding risk.
Clinical Implications: Initiate recombinant thrombomodulin/antithrombin when JAAM-2-DIC criteria are met; avoid empiric anticoagulation in non-DIC sepsis to reduce bleeding. Incorporate JAAM-2-DIC into DIC treatment protocols and stewardship.
Key Findings
- Among 1,903 sepsis patients, anticoagulation improved survival only in those meeting DIC criteria; no benefit in non-DIC patients.
- Bleeding requiring transfusion increased when anticoagulation was given to non-DIC patients but was not elevated in DIC patients.
- JAAM-2-DIC uniquely showed significant effect modification for both efficacy and safety, best identifying patients who benefit from treatment.
Methodological Strengths
- Large-scale nationwide administrative database with Sepsis-3 case definition
- Comparative evaluation across multiple DIC criteria with effect modification analyses
Limitations
- Retrospective observational design with potential residual confounding and coding bias
- Lack of randomized assignment and limited clinical/laboratory granularity
Future Directions: Prospective, preferably randomized or quasi-experimental studies to validate JAAM-2-DIC–guided anticoagulation and to refine thresholds and duration.
BACKGROUND: Disseminated intravascular coagulation (DIC) is a severe complication of sepsis. Recently, the Japanese Association for Acute Medicine (JAAM) DIC criteria were modified into the JAAM-2-DIC criteria. This study aimed to assess the utility of the JAAM-2 DIC criteria as an indicator for initiating treatment for DIC using a large-scale database. METHODS: We analyzed data from the Japanese Administrative Claims Database, which covers approximately 18 million patients from 600 hospitals. Adult patients with sepsis, defined by the Sepsis-3 criteria, were included. The relationship between DIC treatment (recombinant thrombomodulin and antithrombin) and survival, and bleeding complications, including the timing of initiation, was evaluated according to the JAAM-2-DIC, ISTH-overt DIC, and sepsis-induced coagulopathy (SIC) criteria. RESULTS: Among 1903 patients, 415 (22 %) received DIC treatment. At sepsis diagnosis, 673 (35 %), 174 (9 %), and 699 (37 %) patients met the JAAM-2 DIC, ISTH-overt DIC, and SIC criteria, respectively. DIC treatment was associated with improved survival in patients diagnosed with DIC by any criteria but not in those without DIC. In patients without DIC, DIC treatment increased bleeding complications requiring transfusion, whereas this risk was not elevated in patients with DIC. Only the JAAM-2-DIC criteria showed significant effect modification for both efficacy and safety. Initiating DIC treatment based on JAAM-2-DIC criteria most effectively identified patients with a survival benefit. CONCLUSION: The JAAM-2-DIC criteria effectively identify patients with better survival outcomes and a low risk of bleeding among those receiving DIC treatment. These criteria may serve as a useful indicator for starting DIC treatment in this population.
2. Frailty Index-laboratory and lymphocyte subset patterns in predicting 28-day mortality among elderly sepsis patients: a multicenter observational cohort study.
In 1,197 elderly sepsis patients across four centers, higher FI-lab categorization independently predicted 28-day mortality and correlated with depressed lymphocyte subsets, notably NK cells. A combined model using FI-lab, APACHE-II, heart rate, NK count, and pulmonary infection achieved AUC 0.788 with strong internal validation.
Impact: Advances geriatric sepsis risk stratification by integrating frailty biology with immune profiling, offering a pragmatic tool when advanced immunomonitoring is limited.
Clinical Implications: Use FI-lab with basic lymphocyte subset counts (especially NK cells) at ICU admission to stratify 28-day mortality risk, guide triage, monitoring intensity, and early goals-of-care discussions.
Key Findings
- High FI-lab risk group had 28-day mortality of 22.2% vs 12.0% (intermediate) and 6.1% (low).
- All lymphocyte subsets were lower in non-survivors, especially NK cells; NK count independently associated with survival (OR 0.994).
- Combined model (FI-lab, APACHE-II, heart rate, NK count, pulmonary infection) achieved AUC 0.788 with optimism-corrected AUC 0.775.
Methodological Strengths
- Multicenter prospective design with large elderly cohort
- Integration of frailty index and immune phenotyping with internal validation
Limitations
- Observational design limits causal inference; potential unmeasured confounding
- External validation and generalizability beyond Beijing tertiary centers are pending
Future Directions: External validation across diverse health systems and testing FI-lab–guided care pathways for outcome improvement in elderly sepsis.
BACKGROUND: Frailty is associated with poor outcomes in elderly sepsis patients. This study investigated the relationship between Frailty Index-laboratory (FI-lab) and lymphocyte patterns in predicting 28-day mortality among elderly sepsis patients. METHODS: We conducted a multicenter prospective observational study in four tertiary hospitals in Beijing, China. FI-lab was calculated using 24 laboratory parameters. Peripheral blood lymphocyte subsets were measured at ICU admission. Lymphocyte count trajectories were classified into four phenotypes based on patterns during the first 72 hours. The primary outcome was 28-day mortality. RESULTS: Among 1,197 patients (mean age 74.6 ± 7.4 years), those with high FI-lab risk showed higher mortality (22.2%) than intermediate (12.0%) and low-risk groups (6.1%). Age-stratified analysis demonstrated consistent FI-lab prognostic value in both 65-79 years (OR 2.18) and ≥80 years (OR 2.47) groups. All lymphocyte subset counts were lower in non-survivors, particularly natural killer cells. In multivariable analysis, high FI-lab risk (OR 2.31), APACHE-II scores (OR 1.08), heart rate (OR 1.01), NK cell count (OR 0.994), and pulmonary infection (OR 1.96) independently predicted 28-day mortality. A combined model incorporating these variables showed superior discriminative ability (AUC=0.788) with excellent internal validation (optimism-corrected AUC=0.775). CONCLUSIONS: FI-lab independently predicts mortality in elderly sepsis patients and correlates with lymphocyte abnormalities. When comprehensive immune assessment is unavailable, lymphocyte trajectory patterns offer a practical approach for risk stratification.
3. Is restriction of intravenous fluid beneficial for septic shock in ICU patients? A meta-analysis of randomized controlled trials.
Across five RCTs (n=1,972), restrictive fluid resuscitation did not reduce acute kidney injury or ICU mortality versus conventional strategies, nor did it markedly change ventilation or ischemic events. The strategy appears safe, supporting individualized fluid targets rather than uniform restriction.
Impact: Synthesizes randomized evidence on a foundational sepsis intervention, clarifying that restrictive fluids are a safe alternative but not superior, informing guideline discussions.
Clinical Implications: Avoid rigid fluid restriction mandates; tailor resuscitation to perfusion endpoints and patient trajectory, recognizing restrictive strategies are acceptable but not necessarily beneficial.
Key Findings
- Restrictive fluid resuscitation showed no reduction in AKI compared with conventional strategies (RR ~0.92; 95% CI 0.79–1.07).
- ICU mortality did not differ between restrictive and conventional arms across included RCTs.
- Secondary outcomes (need for mechanical ventilation, ischemic events) showed no significant differences, supporting safety of restrictive strategies.
Methodological Strengths
- Meta-analysis of randomized controlled trials with PROSPERO registration
- Comprehensive multi-database search and predefined outcomes
Limitations
- Heterogeneity in restrictive protocols and resuscitation targets across trials
- Limited number of RCTs may reduce power to detect modest benefits or harms
Future Directions: Pragmatic trials testing perfusion-guided, dynamically titrated fluid strategies and standardized definitions of ‘restrictive’ vs ‘conventional’ resuscitation.
BACKGROUND: In this study, we performed a meta-analysis to systematically evaluate how restrictive fluid resuscitation strategies, compared to conventional approaches, affect key clinical outcomes in adult patients with septic shock in the intensive care unit (ICU). The primary outcomes of our analysis included acute kidney injury incidence and ICU mortality, while the secondary outcomes encompassed mechanical ventilation requirement and ischemic event incidence. By comparing the efficacy and safety of the two strategies, this study provides evidence-based support for optimizing fluid management in patients with septic shock. METHODS: A systematic search of the PubMed, Cochrane Library, Web of Science, Embase, and CNKI databases was performed from inception to March 2024. Randomized controlled trials on restrictive fluid resuscitation for septic shock were included. Primary outcomes included acute kidney injury incidence and ICU mortality; secondary outcomes covered mechanical ventilation requirement and ischemic events. The meta-analysis was performed using Review Manager software (version 5.3). RESULTS: Five randomized controlled trials were included in this study, comprising 1972 patients. Compared to the conventional fluid resuscitation group, the restrictive fluid resuscitation group displayed no difference in acute kidney injury incidence (risk ratio (RR), 0.92; 95% confidence interval (CI), 0.79-1.07; P = 0.29; I CONCLUSION: Although restrictive fluid resuscitation did not show superiority over conventional protocols in terms of clinical outcomes, it may represent a safe alternative for ICU patients with septic shock. TRIAL REGISTRATION: The study was registered on PROSPERO (CRD42024515869).